FDA issues warning letter to Smruthi Organics' API plant in India

08:36 AM | March 26, 2014 | Deepti Ramesh

FDA issued a warning letter earlier this month to the active pharmaceutical ingredient (API) manufacturing facility of Smruthi Organics (Solapur, India) located at Solapur, for violations of cGMP. An...